Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Nkarta Inc NKTX

Healthcare Biotechnology
Nkarta, Inc. is a clinical-stage biopharmaceutical company advancing the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies for the treatment of patients with autoimmune diseases or hematologic malignancies. It is developing NKX019, a chimeric antigen receptor-natural killer (CAR NK) product candidate targeting the CD19 antigen and NKX101, a CAR NK product... see more

Recent & Breaking News (NDAQ:NKTX)

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors

Business Wire April 8, 2024

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors

Business Wire April 5, 2024

The Law Offices of Frank R. Cruz Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors

Business Wire April 5, 2024

Nkarta to Participate in Upcoming Investor Conferences

GlobeNewswire April 3, 2024

Nkarta Announces Pricing of $240 Million Underwritten Offering

GlobeNewswire March 25, 2024

Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights

GlobeNewswire March 21, 2024

Nkarta to Participate in Upcoming Investor Conferences

GlobeNewswire February 28, 2024

Nkarta Presents NKX101 Clinical Data at the 2023 American Society of Hematology Annual Meeting & Exposition

GlobeNewswire December 9, 2023

Nkarta Reports Third Quarter 2023 Financial Results and Corporate Highlights

GlobeNewswire November 9, 2023

Nkarta to Participate at Upcoming Investor Conferences

GlobeNewswire November 7, 2023

Lupus Therapeutics Announces Partnership to Support the Evaluation of Natural Killer (NK) Cell Therapy in Lupus Nephritis

PR Newswire October 17, 2023

Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis

GlobeNewswire October 17, 2023

Nkarta to Host Conference Call on Tuesday, October 17 at 8am ET to Discuss Expansion of Clinical Pipeline and Organizational Cost Measures

GlobeNewswire October 16, 2023

Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights

GlobeNewswire August 10, 2023

Nkarta to Participate at Upcoming Investor Conference

GlobeNewswire August 3, 2023

Nkarta Appoints Alyssa Levin Chief Financial and Business Officer

GlobeNewswire July 5, 2023

Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia

GlobeNewswire June 27, 2023

Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX101 NK Cell Therapy Program

GlobeNewswire June 26, 2023

Nkarta Presents NKX019 Clinical Data at the European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma

GlobeNewswire June 10, 2023

Nkarta Reports First Quarter 2023 Financial Results and Corporate Highlights

GlobeNewswire May 11, 2023